What happened
FDA issued a warning letter to Bentley Laboratories following a March 2026 inspection, citing significant CGMP violations for finished pharmaceuticals. FDA found inadequate investigations of out-of-specification stability and cleaning results, deficient root-cause analysis and CAPA, unjustified specification changes, and insufficient quality-unit oversight. The agency also cited inadequate incoming-component identity and impurity testing, reliance on supplier certificates of analysis without establishing reliability, and weaknesses in supplier qualification. Manufacturing and cleaning processes were not adequately validated or revalidated after changes, and validation protocols were not fully executed. FDA also determined that two acne products were unapproved new drugs and misbranded, and acknowledged the firm’s commitment to suspend certain OTC drug production.
Why it matters
From a GMP manufacturing perspective, the letter highlights the importance of scientifically sound OOS investigations, effective CAPA, quality-unit authority, controlled changes, and documented process and cleaning validation. It also underscores robust incoming-material testing and supplier oversight, particularly for components at risk of hazardous impurities. Manufacturers using contract facilities may note FDA’s statement that contractors remain responsible for drug quality. The cited gaps may warrant assessment of distributed-product risks, cross-contamination, and whether customer notification or recall is appropriate.
Key topics: Inadequate OOS investigations and CAPA, Incoming-component testing and supplier reliability, Deficient process and cleaning validation